2023 World Conference on Lung Cancer (Posters)-EP12.01. Predictive and Prognostic Value of Early Skeletal Muscle Loss during First-Line EGFR-TKIs for Advanced Lung Adenocarcinoma

EP12.01. Predictive and Prognostic Value of Early Skeletal Muscle Loss during First-Line EGFR-TKIs for Advanced Lung Adenocarcinoma - PDF(Slides)

Back to course

Pdf Summary

This study aimed to investigate the changes in skeletal muscle mass during first-line treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for advanced lung adenocarcinoma. A total of 104 patients with EGFR-mutant lung adenocarcinoma were evaluated retrospectively. Skeletal muscle was measured using abdominal computed tomography (CT) scans obtained before and during EGFR-TKI treatment. The muscle changes were categorized as muscle loss or muscle stable. <br />The results showed that 40.4% of patients experienced muscle loss, with a median reduction rate of 2.9%. Patients with low muscle density before treatment and those who had Grade 2 diarrhea during treatment were more likely to experience muscle loss. Additionally, the median progression-free survival (PFS) was shorter for the muscle loss group compared to the muscle stable group (9.0 vs 12.0 months). Early muscle loss during treatment was independently associated with shorter PFS for first-line EGFR-TKIs. <br />Furthermore, the muscle loss group had a lower rate of receiving chemotherapy after progression of first-line EGFR-TKIs and shorter overall survival compared to the muscle stable group (20.3 vs 30.3 months). Based on these findings, the study concluded that early skeletal muscle loss is associated with limited survival benefits from EGFR-TKI treatment for advanced lung adenocarcinoma patients. The authors suggest the need for further studies to explore strategies for maintaining muscle mass during EGFR-TKI treatment.

Asset Subtitle

Xin Nie

Meta Tag

Speaker Xin Nie

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

skeletal muscle mass

epidermal growth factor receptor tyrosine kinase inhibitors

EGFR-TKIs

lung adenocarcinoma

abdominal computed tomography

muscle loss

muscle stable

progression-free survival

chemotherapy

overall survival